Spots Global Cancer Trial Database for neurofibromatosis type 2
Every month we try and update this database with for neurofibromatosis type 2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients | NCT01222728 | Neoplasms Nervous System ... Vestibular Dise... | 18 Years - 50 Years | National Institutes of Health Clinical Center (CC) | ||
| Doxycycline in Cutaneous Schwannoma (NF2) | NCT05521048 | Neurofibromatos... | Doxycycline Inj... | 8 Years - | Massachusetts Eye and Ear Infirmary | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | NCT04374305 | Neurofibromatos... Vestibular Schw... Non-vestibular ... Meningioma Ependymoma | Brigatinib Neratinib | 12 Years - | Massachusetts General Hospital | |
| Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma | NCT02282917 | Vestibular Schw... Meningioma Acoustic Neurom... Neurofibromatos... | AR-42 | 18 Years - | Massachusetts Eye and Ear Infirmary | |
| Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | NCT02129647 | Neurofibromatos... Vestibular Schw... | Axitinib | 18 Years - | NYU Langone Health | |
| Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | NCT00589784 | CNS Cancer Meningioma Intracranial He... Hemangioblastom... Neurofibromatos... | Sunitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | NCT02104323 | Vestibular Schw... Neurofibromatos... | Endostatin | 16 Years - 30 Years | Beijing Tiantan Hospital | |
| Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | NCT01345136 | Neurofibromatos... Neuroma, Acoust... | RAD001, everoli... | 16 Years - 65 Years | Jonsson Comprehensive Cancer Center | |
| Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | NCT02934256 | Vestibular Schw... Neurofibromatos... | Icotinib | 16 Years - 50 Years | Beijing Tiantan Hospital | |
| Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients | NCT02589912 | Neurofibromatos... Severe Profound... | Nucleus Profile... | 12 Years - 80 Years | Massachusetts Eye and Ear Infirmary | |
| Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas | NCT01880749 | Neurofibromatos... Vestibular Schw... Meningiomas | RAD001 | 18 Years - | NYU Langone Health | |
| Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas | NCT01880749 | Neurofibromatos... Vestibular Schw... Meningiomas | RAD001 | 18 Years - | NYU Langone Health | |
| Effect of Implant Position on Magnetic Resonance Image Distortion | NCT02246231 | Neurofibromatos... | MR imaging | 18 Years - | Manchester University NHS Foundation Trust | |
| Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | NCT01125046 | Acoustic Schwan... Adult Anaplasti... Adult Ependymom... Adult Grade I M... Adult Grade II ... Adult Meningeal... Adult Papillary... Neurofibromatos... Neurofibromatos... Recurrent Adult... | bevacizumab | 18 Years - | Northwestern University | |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas | NCT05130866 | Neurofibromatos... | REC-2282 Placebo | 12 Years - | Recursion Pharmaceuticals Inc. | |
| Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | NCT01125046 | Acoustic Schwan... Adult Anaplasti... Adult Ependymom... Adult Grade I M... Adult Grade II ... Adult Meningeal... Adult Papillary... Neurofibromatos... Neurofibromatos... Recurrent Adult... | bevacizumab | 18 Years - | Northwestern University | |
| Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas | NCT01767792 | Neurofibromatos... Progressive Ves... | Bevacizumab | 6 Years - | University of Alabama at Birmingham | |
| Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | NCT01345136 | Neurofibromatos... Neuroma, Acoust... | RAD001, everoli... | 16 Years - 65 Years | Jonsson Comprehensive Cancer Center | |
| Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | NCT00589784 | CNS Cancer Meningioma Intracranial He... Hemangioblastom... Neurofibromatos... | Sunitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | NCT01125046 | Acoustic Schwan... Adult Anaplasti... Adult Ependymom... Adult Grade I M... Adult Grade II ... Adult Meningeal... Adult Papillary... Neurofibromatos... Neurofibromatos... Recurrent Adult... | bevacizumab | 18 Years - | Northwestern University | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | NCT04374305 | Neurofibromatos... Vestibular Schw... Non-vestibular ... Meningioma Ependymoma | Brigatinib Neratinib | 12 Years - | Massachusetts General Hospital | |
| WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data | NCT03210285 | Neurofibromatos... Vestibular Schw... Acoustic Neurom... | Whole exome seq... | 1 Day - 99 Years | University Hospital Tuebingen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
